A recent report, which suggested that AURKB inhibition by barasertib stabilizes TP53 in breast cancer [19], led us to hypothesize that the sensitivity to AURKB inhibition in MNA NB cells is mediated by intact TP53 activity. This evidence concerns the gene AURKB and breast cancer.